Q-omics provides the consensus-scored RARB profile across patient tissues and cancer cell-line models. RARB expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RARB is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, RARB RNA expression shows 19,946 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where RARB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RARB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RARB survival associations across molecular data types. RARB RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RARB RNA expression–survival associations across cancer types. High RARB expression shows unfavorable associations in LUAD and STAD, but favorable associations in KIRC, UVM, UCS and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RARB RNA expression.
This table summarizes RARB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RARB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RARB shows lower tumor expression in THCA, KICH, KIRC, BRCA, BLCA and LUAD. The THCA box plot shows higher RARB RNA expression in normal versus tumor tissue (log2 FC = −2.162, t-test p < 0.001).
This table shows molecular features associated with RARB in patient tissues and cancer cell lines. In patient samples, RARB shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RARB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
